PPARG and Hepatic steatosis: In summary, this study confirmed that chronic treatment with pioglitazone, a PPARγ agonist, not only ameliorates systematic insulin resistance and decreases plasma TG but also exacerbates hepatic steatosis and liver lesions in obese diabetic KKAy mice.